Opioid-Induced Constipation Treatment Market
Opioid-Induced Constipation Treatment Market taken for treatment of chronic pain. While they relieve the pain, they can give opioid-induced constipation. The adverse effects associated with the opioids are decreasing gastrointestinal tract’s motility, making patient’s strain, and making of solid discharges. Adults are most likely to prone to opioid-induced constipation owing to less immobility, poor diet, and fluid intake.
The opioid-induced constipation treatment market is growing at a significant rate owing to rise in the aging population using opioid analgesics for chronic pains, prolonged usage of opioids in the treatment of pain are anticipated to boost the global opioid-induced constipation drugs market. In addition to this, launching of newer drugs, growing FDA approvals, positive outcomes in clinical trials, and rise in the healthcare expenditure are expected to propel the opioid induced constipation treatment market. However, lack of awareness regarding OIC in patients, a high cost of newer pharmaceuticals, adverse effects, a risk of heart problems and strokes associated with these drugs and unfavorable reimbursement policies expected to hamper the growth of the opioid-induced constipation drugs market.
The global opioid-induced constipation (OIC) treatment market is divided into-
- Drug type
- Peripherally restricted μ-opioid receptor antagonists
- Non-selective opioid antagonists
- μ -opioid receptor antagonists
- Locally acting chloride channel activators
- Type of formulation
- Route of administration
- Parenteral (Subcutaneous Injection)
- Drugstores, retail pharmacies and hospital pharmacies.
And lastly, on the basis of geographical regions, global opioid-induced constipation (OIC) drugs market has been categorized into following five regions-North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America holds the largest share in the opioid-induced constipation (OIC) treatment market followed by Europe and Asia-Pacific. North America holds the largest share due to expanding the base of opioid-induced constipation patients. Europe accounts for the significant share in the opioid-induced constipation treatment market owing to increased demand for opioid analgesics in various European countries such as UK, France, Spain, Germany etc. However, growing elderly population in India and China, and rise in healthcare spending are creating the huge growth opportunity for the players in Asia-Pacific region. Apart from that, Latin America and the Middle East are the potential areas for the growth of opioid-induced constipation treatment market because of the increase in opioid-induced constipation sufferers.
Some of the key players in the opioid-induced constipation (OIC) drugs market are GlaxoSmithKline plc (U.K.), AstraZeneca U.K), Pfizer Inc. (U.S.), SLA Pharma AG (U.K.), AIKO Biotechnology, Inc. (U.S.), Cubist Pharmaceuticals (Merck & Co.) (U.S.), Takeda Pharmaceutical Company Limited (Japan), Boehringer Ingelheim GmbH (Germany), Valeant Pharmaceuticals International Inc. (Canada), Abbott Laboratories (U.S.), and Cosmo Pharmaceuticals N.V. (Ireland) to name a few.
The global opioid-induced constipation (OIC) treatment market is in the growing stage, several players are actively engaged in the development of the opioid-induced constipation treatment market products. Major acquisitions and collaborations among companies to commercialize opioid-induced constipation drugs market products to drive the market growth. For instance, in 2015, the co-commercialization agreement for Movenpick signed by AstraZeneca and Daiichi Sankyo, and in 2014, the entry of Takeda and Sucampo into a global licensing, development, and commercialization agreement for Amitiza are expected to boost the global opioid-induced constipation treatment market. Launching of new products, approval of new drugs from various regulatory bodies, and pipeline products under clinical trials are the key factors helping the growth of the opioid-induced constipation drugs market.